Reading Time: < 1 minuteIntroduction Hypogonadism, characterized by deficient testosterone production, affects approximately 4-5 million American men, manifesting in symptoms such as fatigue, reduced libido, and diminished muscle mass. Testosterone replacement therapy (TRT), exemplified by Tlando oral capsules (testosterone undecanoate), has emerged as a cornerstone treatment, offering bioavailability advantages over transdermal or injectable alternatives. Intriguingly, emerging dermatological research suggests ancillary benefits on inflammatory skin conditions like atopic dermatitis (eczema), which impacts 10-15% of U.S. adult males. This 18-month prospective cohort study evaluates Tlando's efficacy in ameliorating eczema severity among hypogonadal American men, hypothesizing that normalized androgen levels modulate Th2-mediated inflammation and epidermal barrier function. … Continue reading →